Status:
COMPLETED
High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)
Lead Sponsor:
Philips Respironics
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
Up to 80 years
Phase:
NA
Brief Summary
The purpose of this pilot study is to evaluate the effect of high intensity non-invasive positive pressure ventilation (HINPPV) for stable, hypercapnic COPD patients. The investigators believe that HI...
Detailed Description
The High Intensity Non-invasive Positive Pressure trial is a single arm interventional study. The purpose of this study is to evaluate the effect of High Intensity Non-invasive ventilation (HINPPV) in...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patient diagnosed with chronic obstructive pulmonary disease (COPD)
- Age \< or = to 80 years
- Forced expiratory volume in one second (FEV1) \< 50% of predicted value
- FEV1/Forced vital capacity (FVC) \< 70% of predicted value
- Total lung capacity (TLC) \> 90% predicted by plethysmography
- Body Mass Index (BMI) \< 35
- Patient has provided written informed consent using a form that has been approved by the Internal Review Board (IRB)
- Daytime PaCO2 ≥ 52 mm Hg, at rest on room air (Denver \> 48 mm Hg) with one of the following symptoms of hypercapnia:
- Fatigue
- Sleepiness
- Headaches
- Post hospital discharge at least one month prior to screening visit
- Participant is willing and able to complete all required assessments and procedures
- Participant has no child bearing potential OR a negative pregnancy test in a woman of childbearing potential
- Exclusion Criteria
- FEV1 \< 15% of predicted value
- Diagnosis of obstructive sleep apnea (OSA) \[Apnea hypopnea index (AHI) \> 15 per hour\]
- Current Non-invasive Positive Pressure Ventilation (NIPPV), Positive Airway Pressure (PAP) or Non-invasive Ventilation (NIV) users
- Signs / symptoms of acute exacerbation within the previous month: two of the following criteria:
- Increasing cough
- Purulent sputum
- Current use of antibiotics
- pH \< 7.35
- Any major non COPD disease or condition that interferes with completion of initial or follow-up assessments, such as uncontrolled malignancy, end-stage heart disease, liver or renal insufficiency (that requires current evaluation for liver or renal transplantation or dialysis), amyotrophic lateral sclerosis, or severe stroke, or other as deemed appropriate by investigator as determined by review of medical history and / or patient reported medical history
- History of pneumothorax
- Anatomical facial abnormalities precluding placement of a nasal or facial mask
- Diffuse parenchymal lung disease other than emphysema
- Inability to maintain Oxygen (O2) saturation \>90% on 5L/min ( five liters) nasal O2 at rest
- Sustained need for \>10 mg prednisone daily or equivalent dose of other systemic corticosteroid
- Pregnancy
- Excessive alcohol intake (≥ 6oz hard liquor daily), or illicit drug use
- Daily use of narcotics (greater than 30 mg morphine equivalent)
- Patient is currently enrolled in another interventional clinical trial
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01214200
Start Date
August 1 2010
End Date
December 1 2012
Last Update
January 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140